[go: up one dir, main page]

MXPA05013048A - Composiciones peptodicas farmaceuticas estabilizadas. - Google Patents

Composiciones peptodicas farmaceuticas estabilizadas.

Info

Publication number
MXPA05013048A
MXPA05013048A MXPA05013048A MXPA05013048A MXPA05013048A MX PA05013048 A MXPA05013048 A MX PA05013048A MX PA05013048 A MXPA05013048 A MX PA05013048A MX PA05013048 A MXPA05013048 A MX PA05013048A MX PA05013048 A MXPA05013048 A MX PA05013048A
Authority
MX
Mexico
Prior art keywords
peptide compositions
stabilized pharmaceutical
pharmaceutical peptide
peptide
stabilized
Prior art date
Application number
MXPA05013048A
Other languages
English (en)
Inventor
Claus Juul-Mortensen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MXPA05013048A publication Critical patent/MXPA05013048A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describe un metodo para incrementar la viada en anaquel de una composicion farmaceutica para la administracion parenteral, que comprende un peptido similar al glucagon, que es preparado a partir de un producto peptidico que ha sido sometido a tratamiento a un pH por arriba del pH neutro.
MXPA05013048A 2003-06-03 2004-06-03 Composiciones peptodicas farmaceuticas estabilizadas. MXPA05013048A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200300819 2003-06-03
US47627903P 2003-06-05 2003-06-05
DKPA200400075 2004-01-19
US53852504P 2004-01-22 2004-01-22
PCT/DK2004/000380 WO2004105781A2 (en) 2003-06-03 2004-06-03 Stabilized pharmaceutical peptide compositions

Publications (1)

Publication Number Publication Date
MXPA05013048A true MXPA05013048A (es) 2006-03-02

Family

ID=33494167

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05013048A MXPA05013048A (es) 2003-06-03 2004-06-03 Composiciones peptodicas farmaceuticas estabilizadas.

Country Status (7)

Country Link
EP (1) EP1633390B1 (es)
KR (1) KR101293507B1 (es)
AU (1) AU2004243531B2 (es)
CA (1) CA2527743A1 (es)
MX (1) MXPA05013048A (es)
PL (1) PL1633390T3 (es)
WO (1) WO2004105781A2 (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE382057T1 (de) 2001-06-28 2008-01-15 Novo Nordisk As Stabile formulierung von modifiziertem glp-1
PL1633391T3 (pl) 2003-06-03 2012-03-30 Novo Nordisk As Stabilizowane farmaceutycznie kompozycje peptydowe
KR101308912B1 (ko) 2003-06-03 2013-09-23 노보 노르디스크 에이/에스 안정화된 약학적 펩티드 조성물
SI3300721T2 (sl) 2003-11-20 2025-05-30 Novo Nordisk A/S Peptidne formulacije, ki vsebujejo propilen glikol in ki so optimalne za proizvodnjo in uporabo v napravah za injiciranje
PL1789434T3 (pl) 2004-08-31 2014-07-31 Novo Nordisk As Zastosowanie tris(hydroksymetylo)aminometanu do stabilizacji peptydów, polipeptydów i białek
ES2458991T5 (en) 2004-11-12 2025-10-14 Novo Nordisk As Stable formulations of insulinoptropic peptides
WO2007056362A2 (en) 2005-11-07 2007-05-18 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
EP2124974B1 (en) * 2007-01-05 2017-03-15 Indiana University Research and Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
AU2008216265B2 (en) 2007-02-15 2014-04-03 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
EP2214691B1 (en) 2007-10-30 2015-09-30 Indiana University Research and Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
JP5669582B2 (ja) 2007-10-30 2015-02-12 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ グルカゴンアンタゴニスト
EP2300035B1 (en) 2008-06-17 2015-08-12 Indiana University Research and Technology Corporation Gip-based mixed agonists for treatment of metabolic disorders and obesity
MX337038B (es) 2008-06-17 2016-02-10 Univ Indiana Res & Tech Corp Co-antagonistas de receptor de glucagon/glp-1.
CN104447980A (zh) 2008-06-17 2015-03-25 印第安纳大学研究及科技有限公司 在生理pH缓冲液中具有增强的溶解性和稳定性的胰高血糖素类似物
PT2349324T (pt) 2008-10-17 2017-12-06 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
SG172291A1 (en) 2008-12-19 2011-07-28 Univ Indiana Res & Tech Corp Amide based glucagon superfamily peptide prodrugs
MX2011013625A (es) 2009-06-16 2012-01-20 Univ Indiana Res & Tech Corp Compuestos glucagon activo de receptor de gip.
SG10201500871TA (en) 2009-11-13 2015-04-29 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
WO2011058083A1 (de) 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Pharmazeutische zusammensetzung umfassend einen glp-1-agonisten, ein insulin und methionin
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
JP2013518115A (ja) 2010-01-27 2013-05-20 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション 代謝疾患及び肥満の治療のためのグルカゴンアンタゴニスト‐ｇｉｐアゴニスト複合体及び組成物
ES2661228T3 (es) 2010-05-13 2018-03-28 Indiana University Research And Technology Corporation Péptidos de la superfamilia de glucagón que muestran actividad de receptor nuclear de hormona
RU2012153753A (ru) 2010-05-13 2014-06-20 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Пептиды глюкагонового суперсемейства, обладающие активностью в отношении сопряженных с g-белком рецепторов
CA2796894A1 (en) 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
RS55378B1 (sr) 2010-08-30 2017-03-31 Sanofi Aventis Deutschland Upotreba ave0010 za proizvodnju leka za tretman diabetes mellitus tipa 2
EA201390941A1 (ru) 2010-12-22 2013-12-30 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Аналоги глюкагона, проявляющие активность на рецепторе gip
AU2012213435B2 (en) * 2011-02-02 2017-03-30 Sanofi-Aventis Deutschland Gmbh Prevention of hypoglycaemia in diabetes mellitus type 2 patients
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
MX2013015168A (es) 2011-06-22 2014-03-31 Univ Indiana Res & Tech Corp Co-agonista del receptor de glucagon/glp-1.
ME02816B (me) 2011-06-22 2018-01-20 Univ Indiana Res & Tech Corp Koagonisti receptora za glukagon/glp-1 receptora
US9944687B2 (en) 2011-07-04 2018-04-17 Imperial Innovations Limited Compounds and their effects on feeding behaviour
HRP20151068T1 (hr) 2011-08-29 2016-01-01 Sanofi-Aventis Deutschland Gmbh Farmaceutska kombinacija za upotrebu za glikemijsku kontrolu kod pacijenata s dijabetesom tipa 2
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
HK1198810A1 (en) 2011-11-17 2015-06-12 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
CN104583232B (zh) 2012-06-21 2018-04-13 印第安纳大学研究及科技有限公司 展现gip受体活性的胰高血糖素类似物
IN2015DN00544A (es) * 2012-07-23 2015-06-26 Zealand Pharma As
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
SG11201503526UA (en) 2012-12-21 2015-06-29 Sanofi Sa Dual glp1/gip or trigonal glp1/gip/glucagon agonists
MY180276A (en) 2013-06-28 2020-11-26 Amgen Inc Stable liquid formulation of amg 416 (velcalcetide)
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
TWI758239B (zh) 2014-12-12 2022-03-21 德商賽諾菲阿凡提斯德意志有限公司 甘精胰島素/利司那肽固定比率配製劑
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
MX2020001525A (es) 2017-08-24 2020-03-20 Novo Nordisk As Composiciones de peptido similar al glucagon tipo 1 (glp-1) y sus usos.
WO2020127476A1 (en) 2018-12-19 2020-06-25 Krka, D.D., Novo Mesto Pharmaceutical composition comprising glp-1 analogue
WO2021123228A1 (en) 2019-12-18 2021-06-24 Krka, D.D., Novo Mesto Pharmaceutical composition comprising glp-1 analogue
IL294521A (en) 2020-02-18 2022-09-01 Novo Nordisk As glp-1 compounds and their uses
US20240374690A1 (en) * 2021-01-25 2024-11-14 Mylan Ireland Limited Pharmaceutical Peptide Compositions and Methods of Preparation Thereof
GR1010977B (el) * 2024-05-23 2025-06-13 Φαρματεν Α.Β.Ε.Ε., Παρεντερικο σκευασμα ενος αναλογου του γλυκογονομορφου πεπτιδιου 1 και μεθοδος παραγωγης αυτου

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2312190A1 (en) * 1997-12-05 1999-06-17 Eli Lilly And Company Glp-1 formulations
US6380357B2 (en) * 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
DK1140148T3 (da) * 1998-12-22 2006-01-30 Lilly Co Eli Lagerholdbar formulering af glucagon-agtigt peptid-1
EP1351984A2 (en) * 2000-12-13 2003-10-15 Eli Lilly And Company Amidated glucagon-like peptide-1
US6573237B2 (en) * 2001-03-16 2003-06-03 Eli Lilly And Company Protein formulations
ATE382057T1 (de) * 2001-06-28 2008-01-15 Novo Nordisk As Stabile formulierung von modifiziertem glp-1
US7238663B2 (en) * 2001-08-28 2007-07-03 Eli Lilly And Company Pre-mixes of GLP-1 and basal insulin

Also Published As

Publication number Publication date
CA2527743A1 (en) 2004-12-09
EP1633390B1 (en) 2012-01-18
KR101293507B1 (ko) 2013-08-06
AU2004243531B2 (en) 2009-11-05
AU2004243531A1 (en) 2004-12-09
WO2004105781A3 (en) 2005-03-17
WO2004105781A2 (en) 2004-12-09
PL1633390T3 (pl) 2012-06-29
EP1633390A2 (en) 2006-03-15
KR20060017531A (ko) 2006-02-23

Similar Documents

Publication Publication Date Title
MXPA05013048A (es) Composiciones peptodicas farmaceuticas estabilizadas.
EP2292254A3 (en) Stabilized pharmaceutical peptide compositions
EP2292253A3 (en) Stabilized pharmaceutical peptide compositions
WO2007133637A3 (en) Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
MXPA05006568A (es) Compuestos de pirazol aciclico para la inhibicion de proteina cinasa-2 activada por proteina cinasa activada por mitogenos.
TW200612892A (en) Novel compounds
TW200505837A (en) Novel compounds
UA95644C2 (ru) Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
TW200519075A (en) Novel compounds
MX2009003305A (es) Inhibidores de co-transportador de glucosa de sodio 2 y metodo para su uso.
IN2012DN03085A (es)
MY138708A (en) Biaryloxymethylarenecarboxylic acids
DE60110054D1 (en) Cardioprotektive phosphonate
WO2007100758A3 (en) Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
WO2006058539A3 (en) Growth hormone secretagogue receptor 1a ligands
WO2006099943A8 (de) Amid substituierte 8-n-benzimidazole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
WO2005115470A3 (fr) COMPOSITIONS PHARMACEUTIQUES CONTENANT DES DERIVES DE β-­CARBOLINE, ET LEUR UTILISATION POUR LE TRAITEMENT DES CANCERS
FI20011403A7 (fi) Menetelmä ja koostumukset vatsan sairauksien hoitoon
HK1041816A1 (zh) 药片
EP2215054B8 (en) Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
WO2004087880A3 (en) Compounds and their use to treat diabetes and related disorders
WO2005055939A3 (en) Vinca derivatives
TW200628473A (en) Novel heterocycles
WO2008065485A3 (en) Stable pharmaceutical compositions of a calcium channel blocker and an ace inhibitor

Legal Events

Date Code Title Description
FG Grant or registration